Archives

ADNI began in October 2004. The overall goal is to validate biomarkers for Alzheimer’s disease clinical trials. One aim is to find, validate and standardize more sensitive and accurate methods to detect Alzheimer’s disease at earlier stages and mark its progress through biomarkers. The study gathered and analyzed thousands of brain scans, genetic profiles, and biomarkers in blood and cerebrospinal fluid that are used to measure the progress of disease or the effects of treatment. More information on ADNI-info.org. All data is publically available at USC/LONI/ADNI.

The three overarching longitudinal ADNI study goals are:

Validation of biomarkers, especially for amyloid and tau, for use in AD clinical trials.
To detect Alzheimer’s disease (AD) at the earliest stage possible and identify ways to track the disease through biomarkers.
To support advances in AD intervention, prevention and treatment through the application of new diagnostic methods to apply at the earliest stages technically possible – when intervention may be most effective.
To continually develop ADNI’s now- legendary data access policy and continuously improve and expand the unprecedented data sharing model.

Last update – 07/02/2017

Aims & objective

To find out the known as well as some new factors which increase the risk of occurrence of stroke (half body paralysis, Lakwa) and of memory problem and other brain related problems.
To identify a group of apparently healthy people (50 years and above), carry out their health check up and follow them up over several years to detect any health problems (like heart attack, lakwa, memory problems) with increasing age.
To investigate the prevalence and incidence of and risk factors for stroke and cognitive decline in the elderly.

Updates about the health of the participants will be obtained from telephone follow-ups every six months and physical check-ups every three years. The study is expected to last for at least 10 years.

Last update – 02/02/2017

The DEAS is a nationwide representative survey of the German population aged 40 and older that combines cross-sectional and longitudinal samples. Participants from baseline samples (drawn every six years) are followed up and enter the different panel samples. Panel data was collected at the same time as baseline samples until 2008. Starting from 2011, panel samples are interviewed every three years. Thus, DEAS enables an analysis of social change using the cross-sectional data of 1996, 2002, 2008, and 2014, as well as an investigation of intra-individual development over three to eighteen years (1996-2002-2008-2011-2014).

Last update – 16/02/2017

The Dunedin Multidisciplinary Health and Development Study (DMHDS) is an ongoing, longitudinal study of the health, development and well-being of a general sample of New Zealanders. They were studied at birth (1972-73), followed up and assessed at the age of three when the longitudinal study was established. Since then they have been assessed every two years until the age of 15, then at ages 18 (1990-91), 21 (1993-94), 26 (1998-99), 32 (2003-2005), and 38 (2010-2012). It is planned to next see the Study members at age 44/45 and beyond.

Last update – 31/01/2017

GENFI is a five year longitudinal biomarker cohort study of genetic Frontotemporal Dementia and its associated disorders (including MND/ALS) investigating members of families with a known mutation in GRN or MAPT or an expansion in C9orf72 (including those affected with the disorder as well as at-risk members of families). Non-carrier first-degree relatives will serve as a control group.
All GENFI participants will be assessed longitudinally (annually) with a set of clinical, neuropsychiatric, cognitive, imaging and biosample protocols.

Last update – 25/01/2017

The HCS is a population-based cohort study established to assess factors important in the health, well-being, social functioning and economic consequences of ageing. The participants included community-dwelling men and women aged 55-85 years of age who reside in Newcastle, New South Wales (NSW), Australia. They were randomly selected from the NSW State electoral roll and contacted between December 2004 and December 2007.

The participants’ study data was collected through self-report postal questionnaires which covered a wide range of variables but also linked with local and national health information databases and hospital records. These provided follow-up on use of prescription medication, health service utilization and hospitalizations, morbidity and mortality. There was also a baseline clinic visit which measured a wide variety of parameters including hearing, vision, smell, balance, cognition, and lung function. Medications and diagnoses have been collected not only at baseline but also at periodic intervals during follow-up.

Last update – 31/01/2017

The main objective of the Longitudinal Ageing Study in India (LASI) is to provide comprehensive longitudinal evidence base on health, social and economic wellbeing of elderly population in India.

LASI main wave’s covers 30 states and 6 union territories of India covering a panel sample size of 60,250 elderly persons aged 45 years and above. The long-term goal of LASI is to continue this survey for the next 25 years with the first wave planned in the year 2016-17 and second wave in 2018-19. LASI aims to obtain all the indicators for each of the 30 states and 6 union territories. In addition, LASI aims at obtaining indicators for each of the four metropolitan cities of Delhi, Kolkata, Mumbai and Chennai.

Last update – 10/02/2017

Helsinki Birth Cohort Study (HBCS) 1934-44 is a unique birth study including 13,345 subjects in the epidemiological cohort. The cohort is a longitudinal study cohort with data throughout the life span including prenatal life, early childhood and later life. Besides extensive epidemiological data over 2000 subjects have been randomly selected for a clinical part. The subjects have been followed up clinically for over one decade with extensive phenotypic data available including metabolic data, dietary information as well as other lifestyle data. Psychological factors including personality, depression and anxiety has been focused upon.

Last update – 07/02/2017

The NIMROD (Neuroimaging of Inflammation in Memory and Other Disorders) study aims to understand the role of inflammation in several forms of dementia, memory loss and depression (Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), Parkinsons disease dementia (PDD), progressive supranuclear palsy (PSP), frontotemporal dementia (FTD), late life depression (LLD), mild cognitive impairment (MCI)). It also aims to understand the changes in the immune system, from immune cells and other components in the blood and cerebrospinal fluid.

To achieve this, NIMROD looks at brain changes in dementia, depression and related disorders in several different ways, detecting differences in brain structure and function, measuring inflammation and annual psychology and memory assessments. A further aim is to investigate if neuroinflammation can predict subsequent clinical course, including cognitive and functional decline.

Last update – 01/02/2017

The British Regional Heart Study (BRHS) is a prospective study in middle-aged men drawn from general practices in 24 British towns, 7,735 men were recruited in 1978-1980. It was set up to determine the factors responsible for the considerable variation in coronary heart disease, hypertension and stroke in Great Britain. It also seeks to determine the causes of these conditions in order to provide a rational basis for recommendations towards their prevention.

Following the collection of baseline date in 1978-80 the cohort has been followed up through the participants, two-yearly GP Record Reviews, and the Office of Population and Census Surveys. Participants have been re-contacted through questionnaires or assessment in 1983-85, 1992, 1996, 1998-2000, 2003, 2005, 2007 and 2010-2012, 2014, 2015, 2016.

Last update – 21/02/2017